Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade
Tumor associated neutrophils have been correlated with poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC). Here the authors show that the tyrosine kinase inhibitor lorlatinib modulates neutrophil development and recruitment in the tumor microenvironment, attenuating PDAC progres...
Enregistré dans:
Auteurs principaux: | Sebastian R. Nielsen, Jan E. Strøbech, Edward R. Horton, Rene Jackstadt, Anu Laitala, Marina C. Bravo, Giorgia Maltese, Adina R. D. Jensen, Raphael Reuten, Maria Rafaeva, Saadia A. Karim, Chang-Il Hwang, Luis Arnes, David A. Tuveson, Owen J. Sansom, Jennifer P. Morton, Janine T. Erler |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/80c3347050694832b4503df3a10d5b8d |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
par: Hayato Mizuta, et autres
Publié: (2021) -
CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
par: A. V. Bogolyubova, et autres
Publié: (2015) -
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
par: Haoxin Li, et autres
Publié: (2019) -
Predictors of responses to immune checkpoint blockade in advanced melanoma
par: N. Jacquelot, et autres
Publié: (2017) -
Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
par: Xiaopin Duan, et autres
Publié: (2019)